NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,406,306 | -58.7% | 18,136,735 | 0.0% | 12.88% | -29.3% |
| Q2 2023 | $46,974,144 | -36.5% | 18,136,735 | 0.0% | 18.23% | -31.9% |
| Q1 2023 | $73,997,879 | -18.7% | 18,136,735 | 0.0% | 26.76% | -11.7% |
| Q4 2022 | $91,046,410 | -61.6% | 18,136,735 | 0.0% | 30.31% | -42.3% |
| Q3 2022 | $237,228,000 | +2.0% | 18,136,735 | 0.0% | 52.50% | +6.1% |
| Q2 2022 | $232,513,000 | -6.1% | 18,136,735 | +11.6% | 49.48% | +7.7% |
| Q1 2022 | $247,749,000 | -9.1% | 16,245,817 | +5.5% | 45.93% | +23.9% |
| Q4 2021 | $272,665,000 | -15.7% | 15,396,116 | 0.0% | 37.08% | +0.7% |
| Q3 2021 | $323,626,000 | +6.6% | 15,396,116 | 0.0% | 36.81% | -14.3% |
| Q2 2021 | $303,611,000 | -32.2% | 15,396,116 | 0.0% | 42.97% | +0.2% |
| Q1 2021 | $447,565,000 | -4.1% | 15,396,116 | 0.0% | 42.88% | +1.3% |
| Q4 2020 | $466,502,000 | – | 15,396,116 | – | 42.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $232,513,000 | 49.48% |
| Ponoi II Management, LLC | 1,298,908 | $16,652,000 | 45.25% |
| Ponoi Management, LLC | 1,298,908 | $16,652,000 | 26.29% |
| Euclidean Capital LLC | 746,674 | $9,572,000 | 8.14% |
| StepStone Group LP | 1,573,357 | $20,170,000 | 2.16% |
| First Light Asset Management, LLC | 1,135,884 | $14,562,000 | 1.69% |
| Lexington Partners L.P. | 110,428 | $1,416,000 | 0.73% |
| Rubric Capital Management LP | 797,588 | $10,225,000 | 0.54% |
| Boxer Capital, LLC | 500,000 | $6,410,000 | 0.41% |
| DAFNA Capital Management LLC | 107,653 | $1,380,000 | 0.38% |